Monotherapy of essential hypertension with a converting-enzyme inhibitor

Hypertension

Volumn 5, Issue 5, 1983, Pages III-108-III-113

  Drayer, Jan I M ^a,b   Weber, Michael A ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Captopril; Converting enzyme inhibitor; Hypertension; Monotherapy

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG THERAPY; ESSENTIAL HYPERTENSION; HUMAN; RANDOMIZED CONTROLLED TRIAL; THERAPY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CAPTOPRIL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; PROLINE; RACIAL STOCKS; TIME FACTORS;

EID: 0021087171     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.hyp.5.5_pt_2.iii108     Document Type: Article

References (13)

1. Joint National Committee on Detection: Evaluation and treatment of high blood pressure: report. JAMA 237: 255, 1977
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 248: 2004, 1982
3. Weber MA, Drayer JIM: Antihypertensive agents that act in the central nervous system. Cardiovasc Rev Rep 3: 255, 1982
4. Cody RJ, Tarazi RC, Bravo EL, Fouad FM: Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med 55: 453, 1978
5. Richer C, Doussau MP, Giudicelli JF: Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats. Hypertension 5: 312, 1983
6. Weber MA, Drayer JIM, Priest RT, Chen TJ: Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin converting enzyme. Am J Nephrology 2: 6, 1982
7. Drayer JIM, Weber MA, Lipson JL, Megaffin BB: Differential effects of diuresis and beta-adrenoreceptor blockade during angiotensin converting enzyme inhibition in patients with severe hypertension. J Clin Pharmacol 22: 179, 1982
8. Ames RP, Hill P: Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol 4: S206, 1982
9. Hollifield JW, Sherman K, Slaton P: Age, race and sex as a determinant of successful antihypertensive therapy. Prev Med 7: 88, 1978
10. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 14: 97S, 1982
11. Brunner HR, Gavras H, Waeber B, Textor SC, Turini GA, Wauters JP: Clinical use of an orally acting converting enzyme inhibitor Captopril. Hypertension 2: 558, 1980
12. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA, Gavras H: Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236, 1980
13. Shaper AG, Lewis P: Genetic neutropenia in people of African origin. Lancet 2: 1021, 1971